Legal & General Group Plc Purchases Shares of 259,298 Artivion, Inc. $AORT

Legal & General Group Plc acquired a new stake in Artivion, Inc. (NYSE:AORT) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 259,298 shares of the company’s stock, valued at approximately $5,826,000.

A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Artivion during the 2nd quarter valued at about $149,965,000. Conestoga Capital Advisors LLC purchased a new position in shares of Artivion during the first quarter valued at approximately $43,044,000. Summit Partners Public Asset Management LLC purchased a new position in shares of Artivion during the fourth quarter valued at approximately $39,401,000. Invesco Ltd. raised its holdings in shares of Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after acquiring an additional 317,518 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Stock Performance

Shares of Artivion stock opened at $25.60 on Friday. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.25 billion, a P/E ratio of -365.66 and a beta of 1.25. The business has a fifty day simple moving average of $26.05 and a two-hundred day simple moving average of $29.23. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, equities analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO James P. Mackin sold 70,000 shares of Artivion stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer directly owned 877,275 shares in the company, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president owned 184,118 shares in the company, valued at $5,245,521.82. The trade was a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 114,978 shares of company stock worth $2,965,155. 6.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

AORT has been the topic of several recent analyst reports. Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Citigroup restated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Finally, Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.83.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.